Drugs / MK0777
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00505076 | Jul 2007 → Sep 2009 | schizophrenia | University of California, Los Angeles | Completed | Missed primary |
| Phase 2 | NCT00546624 | Nov 2002 → Feb 2003 | anxiety disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00703833 | Sep 2002 → Feb 2003 | generalized anxiety disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00539578 | Sep 2002 → Feb 2003 | generalized anxiety disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00543920 | Aug 2002 → Feb 2003 | generalized anxiety disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK0777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00539578 ↗ |
| Known as | TPA-023 | ChEMBL registry synonym — accepted as the source's own label CHEMBL200177 ↗ |
| Action | Activate | “MK-0777--a γ-aminobutyric acid (GABA)(A) α2/α3 partial agonist” PMID 21145041 ↗ Dec 2010 |
| Modality | Small molecule | — CHEMBL200177 ↗ |
| Route | Oral | “MK-0777 8 mg tablet by mouth twice daily for 4 weeks” NCT00505076 ↗ |